BRISTOL-MYERS SQUIBB CO (1BMY.MI) Stock Fundamental Analysis
BIT:1BMY - Euronext Milan - US1101221083 - Common Stock - Currency: EUR
Overall 1BMY gets a fundamental rating of 5 out of 10. We evaluated 1BMY against 52 industry peers in the Pharmaceuticals industry. Both the profitability and the financial health of 1BMY get a neutral evaluation. Nothing too spectacular is happening here. 1BMY is valued quite cheap, while showing a decent growth score. This is a good combination! 1BMY also has an excellent dividend rating.
1. Profitability
1.1 Basic Checks
1BMY had positive earnings in the past year.
In the past year 1BMY had a positive cash flow from operations.
The reported net income has been mixed in the past 5 years: 1BMY reported negative net income in multiple years.
In the past 5 years 1BMY always reported a positive cash flow from operatings.
1.2 Ratios
The Return On Assets of 1BMY (-9.66%) is worse than 67.31% of its industry peers.
1BMY's Return On Equity of -54.78% is on the low side compared to the rest of the industry. 1BMY is outperformed by 73.08% of its industry peers.
Looking at the Return On Invested Capital, with a value of 12.54%, 1BMY is in the better half of the industry, outperforming 67.31% of the companies in the same industry.
1BMY had an Average Return On Invested Capital over the past 3 years of 11.67%. This is in line with the industry average of 13.62%.
The last Return On Invested Capital (12.54%) for 1BMY is above the 3 year average (11.67%), which is a sign of increasing profitability.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -9.66% | ||
| ROE | -54.78% | ||
| ROIC | 12.54% |
ROA(3y)1.77%
ROA(5y)0.82%
ROE(3y)-2.38%
ROE(5y)-2.3%
ROIC(3y)11.67%
ROIC(5y)9.83%
1.3 Margins
1BMY has a better Operating Margin (23.90%) than 75.00% of its industry peers.
1BMY's Operating Margin has declined in the last couple of years.
With a decent Gross Margin value of 75.26%, 1BMY is doing good in the industry, outperforming 69.23% of the companies in the same industry.
1BMY's Gross Margin has been stable in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 23.9% | ||
| PM (TTM) | N/A | ||
| GM | 75.26% |
OM growth 3Y-0.56%
OM growth 5Y-4.29%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-1.73%
GM growth 5Y1.42%
2. Health
2.1 Basic Checks
1BMY has a Return on Invested Capital (ROIC), which is just above the Cost of Capital (WACC), which means it is creating some value.
Compared to 1 year ago, 1BMY has less shares outstanding
Compared to 5 years ago, 1BMY has less shares outstanding
Compared to 1 year ago, 1BMY has a worse debt to assets ratio.
2.2 Solvency
1BMY has an Altman-Z score of 2.22. This is not the best score and indicates that 1BMY is in the grey zone with still only limited risk for bankruptcy at the moment.
1BMY has a Altman-Z score (2.22) which is in line with its industry peers.
1BMY has a debt to FCF ratio of 3.56. This is a good value and a sign of high solvency as 1BMY would need 3.56 years to pay back of all of its debts.
With a decent Debt to FCF ratio value of 3.56, 1BMY is doing good in the industry, outperforming 63.46% of the companies in the same industry.
A Debt/Equity ratio of 2.93 is on the high side and indicates that 1BMY has dependencies on debt financing.
Looking at the Debt to Equity ratio, with a value of 2.93, 1BMY is doing worse than 76.92% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 2.93 | ||
| Debt/FCF | 3.56 | ||
| Altman-Z | 2.22 |
ROIC/WACC1.37
WACC9.15%
2.3 Liquidity
A Current Ratio of 1.25 indicates that 1BMY should not have too much problems paying its short term obligations.
1BMY has a worse Current ratio (1.25) than 65.38% of its industry peers.
1BMY has a Quick Ratio of 1.15. This is a normal value and indicates that 1BMY is financially healthy and should not expect problems in meeting its short term obligations.
1BMY has a better Quick ratio (1.15) than 65.38% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.25 | ||
| Quick Ratio | 1.15 |
3. Growth
3.1 Past
The earnings per share for 1BMY have decreased strongly by -84.80% in the last year.
1BMY shows a very negative growth in Earnings Per Share. Measured over the last years, the EPS has been decreasing by -24.57% yearly.
The Revenue has been growing slightly by 7.32% in the past year.
Measured over the past years, 1BMY shows a quite strong growth in Revenue. The Revenue has been growing by 13.06% on average per year.
EPS 1Y (TTM)-84.8%
EPS 3Y-46.63%
EPS 5Y-24.57%
EPS Q2Q%-1.76%
Revenue 1Y (TTM)7.32%
Revenue growth 3Y1.36%
Revenue growth 5Y13.06%
Sales Q2Q%7.54%
3.2 Future
Based on estimates for the next years, 1BMY will show a very strong growth in Earnings Per Share. The EPS will grow by 39.59% on average per year.
Based on estimates for the next years, 1BMY will show a decrease in Revenue. The Revenue will decrease by -4.01% on average per year.
EPS Next Y498.05%
EPS Next 2Y133.71%
EPS Next 3Y75.69%
EPS Next 5Y39.59%
Revenue Next Year-4.64%
Revenue Next 2Y-5.27%
Revenue Next 3Y-3.69%
Revenue Next 5Y-4.01%
3.3 Evolution
When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings ratio is 54.03, which means the current valuation is very expensive for 1BMY.
The rest of the industry has a similar Price/Earnings ratio as 1BMY.
Compared to an average S&P500 Price/Earnings ratio of 29.35, 1BMY is valued quite expensively.
The Price/Forward Earnings ratio is 9.03, which indicates a very decent valuation of 1BMY.
1BMY's Price/Forward Earnings ratio is rather cheap when compared to the industry. 1BMY is cheaper than 88.46% of the companies in the same industry.
The average S&P500 Price/Forward Earnings ratio is at 22.10. 1BMY is valued rather cheaply when compared to this.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 54.03 | ||
| Fwd PE | 9.03 |
4.2 Price Multiples
Compared to the rest of the industry, the Enterprise Value to EBITDA ratio of 1BMY indicates a rather cheap valuation: 1BMY is cheaper than 80.77% of the companies listed in the same industry.
Based on the Price/Free Cash Flow ratio, 1BMY is valued cheaply inside the industry as 92.31% of the companies are valued more expensively.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 8.96 | ||
| EV/EBITDA | 7.71 |
4.3 Compensation for Growth
The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
A more expensive valuation may be justified as 1BMY's earnings are expected to grow with 75.69% in the coming years.
PEG (NY)0.11
PEG (5Y)N/A
EPS Next 2Y133.71%
EPS Next 3Y75.69%
5. Dividend
5.1 Amount
1BMY has a Yearly Dividend Yield of 4.12%, which is a nice return.
1BMY's Dividend Yield is rather good when compared to the industry average which is at 2.86. 1BMY pays more dividend than 84.62% of the companies in the same industry.
1BMY's Dividend Yield is rather good when compared to the S&P500 average which is at 2.33.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 4.12% |
5.2 History
The dividend of 1BMY is nicely growing with an annual growth rate of 11.67%!
Dividend Growth(5Y)11.67%
Div Incr YearsN/A
Div Non Decr YearsN/A
5.3 Sustainability
The earnings of 1BMY are negative and hence is the payout ratio. 1BMY will probably not be able to sustain this dividend level.
The dividend of 1BMY is growing, but earnings are growing more, so the dividend growth is sustainable.
DP-54.35%
EPS Next 2Y133.71%
EPS Next 3Y75.69%
BIT:1BMY (3/3/2025, 7:00:00 PM)
56.73
+1.91 (+3.48%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)
Earnings (Next)
Inst Owners80.77%
Inst Owner ChangeN/A
Ins Owners0.07%
Ins Owner ChangeN/A
Market Cap115.12B
Analysts68.39
Price Target55.91 (-1.45%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 4.12% |
Yearly Dividend2.22
Dividend Growth(5Y)11.67%
DP-54.35%
Div Incr YearsN/A
Div Non Decr YearsN/A
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)16.53%
Min EPS beat(2)13.54%
Max EPS beat(2)19.51%
EPS beat(4)4
Avg EPS beat(4)15.2%
Min EPS beat(4)1.78%
Max EPS beat(4)25.96%
EPS beat(8)7
Avg EPS beat(8)9.24%
EPS beat(12)11
Avg EPS beat(12)8.32%
EPS beat(16)14
Avg EPS beat(16)6.25%
Revenue beat(2)2
Avg Revenue beat(2)5.02%
Min Revenue beat(2)4.41%
Max Revenue beat(2)5.63%
Revenue beat(4)4
Avg Revenue beat(4)4.3%
Min Revenue beat(4)2.53%
Max Revenue beat(4)5.63%
Revenue beat(8)5
Avg Revenue beat(8)1.2%
Revenue beat(12)8
Avg Revenue beat(12)1.22%
Revenue beat(16)9
Avg Revenue beat(16)0.88%
PT rev (1m)1.94%
PT rev (3m)1.94%
EPS NQ rev (1m)-17.01%
EPS NQ rev (3m)-17.01%
EPS NY rev (1m)-3.7%
EPS NY rev (3m)-3.7%
Revenue NQ rev (1m)-9.33%
Revenue NQ rev (3m)-9.33%
Revenue NY rev (1m)-2.63%
Revenue NY rev (3m)-2.63%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 54.03 | ||
| Fwd PE | 9.03 | ||
| P/S | 2.59 | ||
| P/FCF | 8.96 | ||
| P/OCF | 8.23 | ||
| P/B | 7.65 | ||
| P/tB | N/A | ||
| EV/EBITDA | 7.71 |
EPS(TTM)1.05
EY1.85%
EPS(NY)6.28
Fwd EY11.07%
FCF(TTM)6.33
FCFY11.15%
OCF(TTM)6.89
OCFY12.15%
SpS21.92
BVpS7.41
TBVpS-13.02
PEG (NY)0.11
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -9.66% | ||
| ROE | -54.78% | ||
| ROCE | 16.77% | ||
| ROIC | 12.54% | ||
| ROICexc | 14.88% | ||
| ROICexgc | 65.79% | ||
| OM | 23.9% | ||
| PM (TTM) | N/A | ||
| GM | 75.26% | ||
| FCFM | 28.87% |
ROA(3y)1.77%
ROA(5y)0.82%
ROE(3y)-2.38%
ROE(5y)-2.3%
ROIC(3y)11.67%
ROIC(5y)9.83%
ROICexc(3y)13.73%
ROICexc(5y)11.7%
ROICexgc(3y)74.94%
ROICexgc(5y)75.96%
ROCE(3y)15.62%
ROCE(5y)13.15%
ROICexcg growth 3Y-15.94%
ROICexcg growth 5Y3.18%
ROICexc growth 3Y7.54%
ROICexc growth 5Y19.82%
OM growth 3Y-0.56%
OM growth 5Y-4.29%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-1.73%
GM growth 5Y1.42%
F-Score3
Asset Turnover0.52
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 2.93 | ||
| Debt/FCF | 3.56 | ||
| Debt/EBITDA | 2.26 | ||
| Cap/Depr | 13% | ||
| Cap/Sales | 2.58% | ||
| Interest Coverage | 6.41 | ||
| Cash Conversion | 71.84% | ||
| Profit Quality | N/A | ||
| Current Ratio | 1.25 | ||
| Quick Ratio | 1.15 | ||
| Altman-Z | 2.22 |
F-Score3
WACC9.15%
ROIC/WACC1.37
Cap/Depr(3y)12.09%
Cap/Depr(5y)10.53%
Cap/Sales(3y)2.56%
Cap/Sales(5y)2.31%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-84.8%
EPS 3Y-46.63%
EPS 5Y-24.57%
EPS Q2Q%-1.76%
EPS Next Y498.05%
EPS Next 2Y133.71%
EPS Next 3Y75.69%
EPS Next 5Y39.59%
Revenue 1Y (TTM)7.32%
Revenue growth 3Y1.36%
Revenue growth 5Y13.06%
Sales Q2Q%7.54%
Revenue Next Year-4.64%
Revenue Next 2Y-5.27%
Revenue Next 3Y-3.69%
Revenue Next 5Y-4.01%
EBIT growth 1Y6.4%
EBIT growth 3Y0.79%
EBIT growth 5Y8.21%
EBIT Next Year276.32%
EBIT Next 3Y53.27%
EBIT Next 5Y27.81%
FCF growth 1Y10.2%
FCF growth 3Y-2.91%
FCF growth 5Y14.03%
OCF growth 1Y9.6%
OCF growth 3Y-2.14%
OCF growth 5Y13.49%